Breakthrough innovations for exceptional patient outcomes
SoranusMed has dedicated itself to achieving exceptional patient outcomes through breakthrough innovations.
​
Founded by a leading academic surgeon and a team of healthcare professionals with engineers, the company developed products with the insight of patients and the physicians who cared for them.
​
Medical Devices in the fields of Urogynecology and Urology
We are developing breakthrough medical devices in the fields of urogynecology and urology, for conditions affecting millions of women and men in the world.
​
​
Medical Devices Portfolio
Current urogynecology portfolio of SoranusMed consists of 3 medical devices in 3 main fields, including next generations of all in the R&D pipeline.
1) Breakthrough surgical treatment of female Stress Urinary Incontinence (SUI).
2) Neuromodulation system for non-invasive transcutaneous treatment of Overactive Bladder (OAB).
3) Surgical treatment of female Pelvic Organ Prolapse (POP).
Revolutionary Medical Devices
Surgical Device for
Stress Urinary Incontinence
Vaginal Arcocolposuspension (VACS) is the new, innovative, mesh-free, natural tissue repair technique, performed through the vaginal route, developed by SoranusMed, to treat women suffering from SUI.
SoranusMed Device was tested in a cadaver study aiming to demonstrate the structural changes in the paraurethral area and the Retzius space following VACS and abdominal Burch colposuspension using MRI-based analysis. VACS demonstrated significant mediolateral approximation without excessive anteroposterior elevation. The reduction in Retzius space volume suggests increased vesicovaginal fascia per unit volume, enhancing pelvic stability. This alignment may optimize bladder neck stability by promoting timely activation of the levator ani muscle, which is essential for continence.
VACS technique and the breakthrough SoranusMed Device developed for the treatment of SUI were also tested in a randomized clinical trial and compared to Transobturator Tape (TOT), and thus clinically proven. SoranusMed Device was shown to be equally effective in all objective outcome measures assessing treatment success in terms of dryness. Patients report relief from involuntary urine leakage, improved QoL, emotional wellbeing,
and sexual health on par with TOT.
SoranusMed Device has demonstrated enhanced safety by eliminating the use of mesh slings, thereby eradicating mesh-related injuries and outcomes. Soranus Device was also shown to significantly reduce voiding difficulty, while being favorable in alleviating pain and discomfort in the lower abdominal area.
Clinical Evidence
​The VACS procedure has been evaluated in a randomized clinical study comparing VACS with the standard transobturator tape (TOT) technique for the treatment of stress urinary incontinence.
Results from 48-month follow-up indicate that the clinical improvements observed after surgery were sustained over time. Objective outcomes demonstrated comparable effectiveness, while several patient-reported measures—including urgency distress, quality of life, and patient satisfaction—showed favorable results for the VACS group.
Safety observations also suggested a potentially improved safety profile compared to a standard of care mesh procedure, particularly regarding voiding symptoms. As a mesh-free invention, no mesh-related complications were observed in the VACS group during the study period.
SmartUric
A Common and Under-Treated Condition
Overactive bladder (OAB) is characterized by a sudden urge to urinate that can be difficult to control and may lead to urinary urgency, urinary frequency, and urge urinary incontinence. The condition affects a large number of adults worldwide and can significantly impact daily life and quality of life. Although several treatment options are available, many patients discontinue therapy or remain untreated. Pharmacological treatments may lead to side effects that limit long-term adherence, while procedural therapies can be invasive, costly, or require repeated clinic visits. As a result, a substantial proportion of patients continue to experience symptoms without receiving sustained treatment.
A Our Approach: SmartUric
​SmartUric is being developed to provide neuromodulation therapy through transcutaneous stimulation of the posterior tibial nerve, a recognized pathway used in the management of overactive bladder. Unlike traditional percutaneous tibial nerve stimulation approaches that typically require needle electrodes and repeated clinic visits, SmartUric is designed as a wearable, non-invasive system intended for use prescribed by a physician and can be used almost anywhere convenient for the patient. Unlike current medications, SmartUric does not cause any of their side effects that mostly result in poor treatment compliance and outcomes.The SmartUric concept focuses on simplifying treatment delivery while maintaining clinical oversight.
Key features of the SmartUric
system include:
​
-
Skin-applied stimulation without needle electrodes
-
Wearable device designed for patient comfort and mobility
-
Physician-prescribed therapy for home-based use
-
Digital tools that may support treatment monitoring and adherence
-
Data collection capabilities to support physician follow-up
By reducing procedural complexity and treatment burden, SmartUric aims to support broader access to neuromodulation therapy for patients living with overactive bladder.
The Unmet Need
​• Overactive bladder affects a large proportion of the adult population worldwide
• Many patients discontinue drug therapy due to tolerability issues
• Only a small percentage proceed to procedural treatments
• A significant number of patients remain untreated or undertreated
Surgical Device for
Pelvic Organ Prolapse
The most common causes of pelvic organ prolapse include pregnancy, labor, and childbirth. There are few and difficult treatments available for this condition, which affects millions of women around the world.
​
We are nearing the end of the process of developing a revolutionary device for pelvic organ prolapse treatment.
The Opportunity
Pelvic floor disorders such as stress urinary incontinence and overactive bladder affect a large and growing patient population worldwide. Demographic trends—including aging populations and increasing awareness of women’s health—are expanding the demand for effective treatment options.
Despite the significant need, many patients remain untreated or discontinue therapy due to limitations associated with existing treatments. This gap highlights a significant opportunity for innovative, patient-centered medical technologies designed to improve treatment accessibility and outcomes.
Our Technology Approach
​​SoranusMed develops clinically informed medical technologies designed to address key challenges in pelvic health. Our approach focuses on patient-centered solutions built on minimally invasive design principles and supported by intellectual property strategies that protect core innovations.
Further technical details regarding the underlying technologies may be shared with qualified partners and investors upon request.
Development Pathway
SoranusMed follows a structured development pathway that integrates clinical insight, engineering development, and regulatory awareness. Technology development progresses through stages such as concept development, preclinical evaluation, clinical validation, and engagement with regulatory frameworks.
This staged approach supports responsible technology development while maintaining a focus on patient safety and clinical value.
Investors & Strategic Partners
SoranusMed is open to collaboration with strategic partners who share the goal of advancing innovative solutions in pelvic health. Potential collaborations may include clinical partnerships, manufacturing relationships, and investments for technology development. Interested partners and investors are invited to contact us to learn more about the company’s technology platform and development vision.
Meet the Team
SoranusMed brings together clinicians, researchers, and strategic advisors with extensive experience in pelvic health, surgical practice, and medical technology development. This multidisciplinary team combines clinical insight, scientific expertise, and industry perspective to guide the development of innovative treatment approaches addressing significant unmet needs in pelvic health.
By integrating medical expertise with technology development, the team works to advance solutions designed to improve patient care and expand treatment possibilities. The team is supported by international advisors with experience in clinical practice, medical device innovation, and healthcare strategy.
Medical Advisors​
Work with Us
We welcome engagement with organizations and individuals interested in advancing innovation in pelvic health.
Potential areas of collaboration include:
• Strategic partnerships
• Clinical collaboration
• Manufacturing partnerships
• Investment opportunities
To schedule a meeting with us, please fill in your contact details
Soranus Ar-Ge A.S.
Erzene Mh. Ankara Cd. 172/67 No: 209 Izmir, Turkey
“This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 954909”
